Adjuvant icis plus targeted therapies reduce hcc recurrence after hepatectomy in patients with high risk of recurrence

HIGHLIGHTS

• who: Jianming Yang et al. from the Department of Hepatic Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China have published the research work: Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence, in the Journal: (JOURNAL) of 21/09/2022
• what: The aim of this study was to investigate the benefits and safety of applying plus targeted therapies after hepatectomy for patients at high risk of HCC Methods: A total of 196 patients with any risk factors for recurrence who underwent hepatectomy for . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.